Trastuzumab mafodotin clinical trials
How each study uses trastuzumab mafodotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trastuzumab mafodotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · Iksuda Therapeutics Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antihistamines source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test trastuzumab mafodotin.
- Dec 2026IKS014 in Advanced Solid Tumors That Express HER2Phase 1 · Iksuda Therapeutics Ltd.
Studies
Open first, then newest update. How each study uses trastuzumab mafodotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- IKS014 in Advanced Solid Tumors That Express HER2RecruitingPhase 1Iksuda Therapeutics Ltd.NCT05872295Written as IKS014How we know
- FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT05755048Written as Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)How we know
- Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.CompletedPhase 1Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT03944499Written as FS-1502How we know
Codes
What other systems call trastuzumab mafodotin · ClinicalTrials.gg INT016602
- UNII (FDA) FWA9E3VB3KTRASTUZUMAB MAFODOTINOne source FDA
- NCI Thesaurus C218975Trastuzumab MafodotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FWA9E3VB3K | TRASTUZUMAB MAFODOTIN | One source FDA |
| NCI Thesaurus | C218975 | Trastuzumab Mafodotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.